However, despite advances in immunotherapy, the vast majority of patients with NSCLC experience disease progression,3, 4, 5, 6 and effective treatment options after progression on anti-PD-(L)1 ICIs are needed.7 Here, CD274 is linked to non-small cell lung carcinoma.